Introduction
It has been described that the central nervous system is a target or source of lymphokines (1) (2) (3) (4) (5) . Receptors for IL-I and IL-2 have been found in the central nervous system, mainly localized in the hippocampus (5) (6) (7) (8) . IL-I(# immunoreactive fibers were found in the hypothalamus, innervating key endocrine cell groups (9) . Rat medial basal hypothalamic cultures release IL-6 and express its mRNA (10) . Recently, IL-1 and IL-6 pro-duction by pituitary cells has been demonstrated. IL-Ij3 immunoreactive material and mRNA was found in rat pituitaries and shown to increase after bacterial lipopolysaccharide treatment of the rats (11) . IL-I receptors were characterized in mouse pituitary cells and AtT-20 corticotrophs (12) . IL-6 production and stimulation by IL-I has been demonstrated in rat anterior pituitary cells (13) (14) (15) (16) (17) . The expression ofIL-6 mRNA in rat anterior pituitary (10) and corticotrophic adenoma (18) cell cultures and the release of IL-6 from human pituitary adenoma cultures (19) have also been reported. The stimulatory action of IL-1 on the hypothalamo-pituitary-adrenal axis has been extensively studied. Despite discrepancies in the literature, it seems to act at the hypothalamic, pituitary, and adrenal levels to induce corticotropin-releasing hormone (nCRHe), corticotropin (ACTH), and cortisol production (20, reviewed in 21 and 22) . Similar results were found for IL-6 (21 and 22) . It was postulated, therefore, that IL-I and IL-6 may be involved in the paracrine or autocrine regulation of pituitary function (11, 14) . IL-2 also acts on the hypothalamo-pituitary-adrenal axis. It has been shown to enhance proopiomelanocortin gene expression (23, 24) and to induce ACTH release in the AtT-20 murine cell line and in rat anterior pituitary cell cultures (25) (26) (27) . In the latter, it also induces the release of other hormones, such as prolactin (25, 28) . When administered to human cancer patients, it increases f3-endorphin, ACTH, and cortisol levels (29, 30) . Further, it stimulates f3-endorphin and ACTH levels in allografted (31) and normal (32) rats, respectively. Several reports, however, failed to find effects of IL-2 in these systems, though more recently, a report suggests that this may be related to species-specific IL-2 forms (32) . Here it was shown that while rat IL-2 enhances ACTH release in rats, human (hu) IL-2 has no effect on rat ACTH levels (32) . As IL-I and IL-6 are localized in pituitary cells, and as a protein related to the a-chain of the IL-2 receptor (IL-2R) has been shown in these cells (27) , we have investigated whether IL-2 and its receptor could be synthesized by pituitary cells. Methods Patients. Nine patients (eight women and one man) aged 16-55 yr, with typical features of chronic hypercortisolism, including facial and truncal obesity and hypertension, were studied. Ofthese patients, eight had hypogonadism and two had hypothyroidism. The presence of a corticotrophic adenoma was suspected by endocrine evaluation. Mean plasma cortisol concentrations, derived from five measurements at 4-5-h intervals within a 24-h period, were determined in the immediate preoperative period and showed a canceled dtUrnal rhythm ofsecretion. The range of mean plasma cortisol concentrations was 486-1,242 nmol/liter (normal: 250-650 nmol/liter). A low dose dexamethasone (2 mg) suppression test failed to produce suppression of cortisol secre-1. Abbreviations used in this paper: CRH, corticotropin-releasing hormone; hu, human; IL-2R, IL-2 receptor; POMC, proopiomelanocortin.
tion. In the insulin-hypoglycemia test (0.15 IU/kg body wt), patients did not show an appropriate response ofcortisol secretion. The range of basal plasma ACTH concentrations was 10-50 pmol/liter (normal: 4-17 pmol/liter). All patients responded to a large dose ofdexamethasone (8 mg) with a significant decrease in plasma cortisol levels. In addition, every patient was subjected to a sinus-petrosus-inferior catheterization in combination with a CRH stimulation test for the determination of pituitary origin and localization of ACTH secretion. Radiological investigation consisted of a nuclear magnetic resonance scan. All patients were persistently cured after transsphenoidal microsurgery.
Tumors. After surgery the adenoma tissue was transported in the sterile culture medium described below. Routinely, the tumor transport medium and the conditioned medium obtained after 24 h of culture as described below, were assayed for all anterior pituitary hormones. The nine tumors were selected for these studies because they had no detectable levels of prolactin, luteinizing hormone, folliclestimulating hormone, growth hormone, and thyroid-stimulating hormone, in contrast to high ACTH levels (> 2,000 pmol/liter), in both transport and conditioned medium. In addition, in three ofthese nine cases, where enough material was present, immunocytochemical studies were performed, confirming that > 95% of the cells were corticotrophs.
Cell cultures. Unless stated, materials and reagents were from Flow Laboratories (Meckenheim, FRG), Seromed (Berlin, FRG), Gibco Laboratories (Karlsruhe, FRG), Falcon Labware (Heidelberg, FRG), and Nunc (Wiesbaden, FRG). Pituitary cell culture was performed as previously described (33, 34) . In brief, for the preparation of human corticotrophic cells, the tissue was washed several times with preparation buffer (137 mM NaCl, 5 mM KCI, 0.7 mM Na2HPO4, 10 mM glucose, 15 mM Hepes pH 7.3, antibiotics). Sliced fragments were dispersed mechanically and enzymatically in preparation buffer containing 4 g/liter collagenase (Cooper Biomedical, Inc., Malvern, PA), 10 mg/liter DNAase II, 0.1 g/liter soybean trypsin inhibitor and I g/liter hyaluronidase. Cells were centrifuged and resuspended in culture medium (DME) containing 10% FCS, 2.2 g/liter NaHCO3, 10 mM Hepes, 2 mM glutamine, 10 ml/liter nonessential amino acids, 10 ml/liter minimal essential medium vitamins, antibiotics, 5 mg/liter insulin, 20 sg/liter selenium, 5 mg/liter transferrin, and 30 pM triiodothyronine (Henning, Berlin, FRG), pH 7.3). Between 3 and 6 X 106 cells with a viability ofat least 80% (acridine orange/ethidium bromide staining) were isolated, distributed (2 x I05 viable cells/ml) to 24-well culture plates or, for immunofluorescence studies, in slide flasks and incubated (37°C, 5% CO2). Few cells could be isolated from each microadenoma, preventing many parallel experiments. For rat anterior pituitary cells, glands were obtained from male Sprague Dawley rats (200-300 g) within minutes of death by decapitation and were treated as described for adenomas. Both human and rat pituitary cells attached to the dishes within 48-72 h and were used 4-6 d after plating. The pituitary preparations were free of lymphocyte contamination as they were < 1% reactive by immunofluorescence with the following monoclonal antibodies (Dianova, Hamburg, FRG): CD2, CD4, CD8, CD14, CD19, and CD45 which define antigens on T cells/NK cells, T helper lymphocytes, T cytotoxic/suppressor cells, monocytes/macrophages, B cells, and leukocytes (leukocyte common antigen), respectively. AtT-20, a mouse corticotrophic tumor cell line, was obtained from the American Type Culture Collection (ATCC, Rockville, MD) and cultured under the same conditions. For all experiments, using the three types of pituitary cultures, after washing the cells, medium was replaced by an experimental medium consisting of DME containing 0.5 g/liter BSA, 2.2 g/liter NaHCO3, 30 Mg/ml ascorbic acid, and 10 mM Hepes, pH 7.3, alone or with phorbol myristate acetate (PMA) (Sigma Chemical Co., St. Louis, MO) or hu CRH (Bachem, Bubendorf, Switzerland). PBMC from healthy donors, mouse and rat spleen cells, were cultured with PHA, 10 Ag/ml (for PBMC) or Con A, 2.5 ,ug/ml (for spleen cells) (Sigma Chemical Co.) as described (35, 36) .
Mouse 3T3 fibroblasts were cultured identically to the AtT-20 cells. RNA analysis. Unless stated, reagents were from Sigma Chemical Co., Boehringer Mannheim Gmb H (Mannheim, FRG), or Pharmacia Fine Chemicals (Uppsala, Sweden). Total RNA was isolated by the guanidine isothiocyanate followed by phenol-chloroform method (37) . RNA extraction, electrophoresis, blotting, radiolabeling of probes, and hybridization were performed as described (33, 34) . Briefly, 5-10 sg RNA was denatured with glyoxal, electrophoresed on a 1.2% agarose gel, and transferred overnight to a nylon membrane: Hybond-N (Amersham International, Amersham, UK) or Nytran-N (Schleicher and Schuell, Dassel, FRG). Filters baked for 2 h at 80'C were prehybridized for 4 h at 60C (50% formamide, 5X sodium chloride sodium phosphate EDTA buffer [SSPE], 5X Denhardt's solution, 0.1% SDS, 100 Ag/ml denatured salmon sperm DNA) and then hybridized with the addition of the probe at the same temperature for 12 h. Blots were washed at increasing salt and temperature stringency with a final wash of 30 min at 60C in 0.1X standard saline citrate (SSC) containing 1% SDS. Dried filters were exposed to Kodak XAR5 film at -70'C with intensifying screens for 6 h-4 d. Single-stranded antisense RNA probes were synthesized using T3 RNA polymerase and . The size of the bands were estimated in several blots by comparison to a RNA ladder. The autoradiograms were scanned with a laser densitometer (Ultroscan II; LKB Instruments Inc., Uppsala, Sweden). The blots were reprobed after eluting the first probe with 5 mM Tris/HCI pH 8.0, 2 mM EDTA, 0.1X Denhardt's solution, at 65°C for 2 h. After the previous signal was removed, confirmed by reexposure ofthe filter, the blots were prehybridized and hybridized following methods described above. Controls with both the 28s-1 8s and the POMC probes were performed in all the blots from adenoma and AtT-20 cells.
IL-2 and IL-2 R determinations. Both IL-2 and IL-2R were determined by RIA and immunofluorescence respectively, as described (34, 35) . Only species-homologous antibodies were used for each cell system. The adenoma supernatants were stored at -20°C until measurement by a RIA with anti-hu IL-2 antibody (Medgenix, Fleurius, Belgium). No interference or cross-reaction with the experimental medium, ACTH (up to 1 gg/ml), IL-I or IL-6 was observed. The detection limit for this assay was 0.5 IL-2 U/ml. For IL-2R studies, after fixing the cells in formaldehyde-acetone, the antibody at serial dilutions was added for 30 min at 37°C. Cells were extensively washed with PBS alone and with PBS containing 1% Triton. Microscopy was performed (magnification, 500) with a Zeiss III RS (Gottingen, FRG) microscope. For the human cells an FITC-conjugated monoclonal mouse antibody, anti-hu p55 (TAC) subunit of the receptor was used (Immunotech, Marseille, France). For the mouse cells, a monoclonal rat anti-mouse TAC first antibody (PC6 1 5.3) produced by the hybridoma cell line TIB 222 (ATCC) and a FHTC-conjugated goat anti-rat second antibody (Dianova) were used. For the rat cells an FITC-conjugated monoclonal mouse anti-rat TAC antibody was used (OX39; facturers, were used at equivalent concentrations. As positive controls, stimulated PBMC, mouse and rat spleen cells were used. For dual immunofluorescence, fixation and washing were performed in the same way. Cells were preabsorbed for 1 h with 10% normal goat serum and incubated overnight with a rabbit anti-ACTH antibody generated as described (33, 34) . After washing, a rhodamine-conjugated goat antirabbit IgG second antibody (Dianova) was added for 1 h at 370C. Cells were washed and treated with the OX39 antibody. Dual immunofluorescence microscopy was performed (magnification, 400) with an Olympus IMT-2 (Tokyo, Japan) microscope. Soluble IL-2R was measured by an immunoenzymometric assay (Immunotech).
Statistics. Statistics were performed by analysis ofvariance in combination with the Scheffe's test. Data are shown as mean±standard deviation.
Results
IL-2 mRNA detection in pituitary cells. A single band of 1 kb, identical to that obtained with PHA-stimulated PBMC, was detected when RNA from human corticotrophic adenoma cells, stimulated for 24 h with CRH, was hybridized with hu IL-2 antisense RNA (Fig. 1 A) . Two bands of ribosomal RNA identical for both pituitary and lymphocyte preparations can be observed after reprobing with a 28s-18s cDNA (Fig. 1 B) .
The same single band was obtained when hybridizing RNA from mouse AtT-20 corticotrophs stimulated for 24 h with CRH or PMA, with a mouse IL-2 cDNA (Fig. 2 A) . To assess the normal function ofthe cells and the specificity ofthe hybridization, the filter was reprobed with a POMC cRNA. The classical pattern resulted (44) : basal POMC mRNA expression, further stimulated with CRH or PMA (Fig. 2 B ; note different exposure times in Fig. 2, A and B ). Blots ofRNA from mouse 3T3 fibroblasts, cultured as negative controls in the same way as the AtT-20 cells, were per- formed and no signal was detected with the mouse IL-2 probe ( Fig. 3 A) . The integrity of the RNA preparation was controlled with the 28s-18s probe (Fig. 3 B) .
In the adenoma cells, in contrast to the AtT-20 cells, after 24 h in experimental medium, there is a basal IL-2 mRNA expression that is not further stimulated with CRH, but is signif- Fig. 2 A the autoradiograms were revealed after 2 d of exposure. (B) The same Northern blot as in A, but completely eluted of radioactivity and reprobed with a 28s and part of 18s 32p_ labeled cDNA. The filter was hybridized and washed as in A and exposed for 6 h. Similar results were obtained with two different 3T3 cell preparations.
icantly stimulated with PMA ( Fig. 4, A and B) . CRH stimulation of IL-2 mRNA was only observed in one adenoma cell preparation.
The same respective patterns, with less intense signals, were obtained for both the human adenomas and AtT-20 cells after 6 h stimulation (data not shown).
IL-2 secretion by human corticotrophic adenoma cells. IL-2 secretion in the 24-h supernatants ofadenoma cells cultured in experimental medium, showed a similar pattern as mRNA expression: basal secretion of IL-2 that is significantly stimulated by PMA (Table I) . The maximum levels detected were 1-1.8 U/ml, about five times lower than those detected for 18 h PHA-stimulated PBMC (5.25±0.75 U/ml IL-2; 106 cell/ml). In two adenomas, one corresponding to CRH-stimulated IL-2 mRNA and the other where no RNA was extracted, CRH also Fig. 1 A. (B) Laser densitometer analysis of the autoradiogram ofA performed after assuring, by the signal intensity of the 28s and 1 8s rRNA, that equal amounts of RNA were loaded in each lane. A significant PMA stimulation can be observed with respect to basal levels. CRH and PMA: 10 nM. *P < 0.05. Similar results were obtained with six different adenoma cell preparations.
In one of them significant stimulation with respect to basal was also observed with CRH. significantly stimulated IL-2 levels with respect to the basal condition (Table I) .
IL-2R mRNA detection and membrane expression in pituitary cells. When hybridized with an a (p55) hu IL-2R cDNA, RNA from human adenoma cells after 6 h at both basal and stimulated conditions gave only the 3.5-kb band, out ofthe two detected in PBMC ( Fig. 5 A) . Similar results were obtained with an a (p55) mouse IL-2R cDNA in 6 h RNA preparations from AtT-20 cells, in which two bands of 4.5 kb and 2.2 kb, that correspond to two bands out of four detected in Con Astimulated mouse spleen cells, are observed ( Fig. 5 B) . In both pituitary cell types, PMA also stimulated IL-2R mRNA expression (data not shown). A single hybridizing band of -3.5 kb, identical to the PBMC larger band, is observed in the adenoma cells. Similar results were obtained in two different cell preparations.
(B) Northern blot of RNA (10 jug total RNA per lane) extracted from mouse spleen cells stimulated for 18 h with Con A (2.5 Mg/ml) (lane 1) or the mouse corticotrophic tumor cell line AtT-20 stimulated for 6 h with CRH (10 nM) (lane 2). After hybridizing with a 0.42-kb 32P-labeled mouse IL-2R cDNA at 60°C and washing at high stringency, the autoradiograms were obtained after 2 d of exposure. Two bands of4.5 and 2.2 kb, identical to that present in the mouse spleen cells, are observed in the AtT-20 cells. Similar results were obtained in four different cell preparations, in which basal expression was observed, and also with the use of another mouse IL-2 R cDNA, a 0.38-kb 32P-labeled fragment. Cells 1947   i   I   I   I I   I Immunofluorescence studies, performed in both the adenoma and the AtT-20 cells with human and mouse monoclonal antibodies, respectively, show that pituitary cells express the receptor on the membrane (Fig. 6 ). For all experiments, over the whole slide area, positive cells were -10% under basal conditionsand -40% under stimulation. In both cell types, there were no distinct differences in the extent of IL-2R positive cells after CRH or PMA stimulation.
Interleukin-2 Pathway Expression in Anterior Pituitary
To complement the study, IL-2R expression on normal rat pituitary cells was assessed (Fig. 7, A and B) . About 10-20% of the basal or CRH-stimulated cells and 50% ofthe PMA-stimulated cells, none ofthem fibroblasts, were positive for the IL-2R antibody. Dual immunofluorescence showed co-localization of the IL-2R with ACTH-positive cells and additional cells expressing the receptor (Fig. 7, C-F) .
Using an antibody ofthe same isotype as the corresponding anti-IL-2R antibody 100% negative cells were observed for all the conditions, confirming the specificity of immunostaining. In addition, negative immunostaining was observed when second antibodies were added without previous addition of the primary antibody. In the 24-h supernatants of the adenoma cells, soluble IL-2R was not detectable.
Discussion
IL-2 is a potent immunoregulatory cytokine critically involved in T cell activation. Its biological effects are mediated by specific receptors on target cells. Both IL-2 and IL-2R have been biochemically characterized and molecularly cloned and their interaction has been shown to be essential for the development of a normal immune response (45, 46) . Neither their production nor their action seems to be confined to the immune cells since they have been detected in normal rat and human brains and brains ofpatients with neurological disease ( 1, 3, 5) . In the present report we describe, for the first time, the presence of IL-2 and IL-2R transcripts, as well as IL-2R membrane expression, in pituitary cells ofdifferent species: mouse AtT-20 corticotrophs and human corticotrophic adenoma cells. In the human adenoma cells IL-2 secretion was shown. Complementary to this, membrane expression of IL-2R in normal rat anterior pituitary cells and its colocalization with ACTH-secreting cells is described. The tumor origin ofboth corticotrophic cell types studied does not, however, allow us to be conclusive about the expression of the complete IL-2 pathway in normal pituitary cells. Moreover, we cannot exclude the possibility that other normal or tumor pituitary cell types also secrete IL-2. Although fibroblasts and endothelial cells were shown to produce IL-6 but not IL-2 (47, 48) , we confirmed the absence of the IL-2 mRNA levels in mouse 3T3 fibroblasts, as a negative control, since primary pituitary cultures contain fibroblasts.
IL-2 at picomolar concentrations not only regulates ACTH, but also prolactin, luteinizing hormone, follicle-stimulating hormones, growth hormone, and thyroid-stimulating hormone secretion (25) . It was concluded that the release pattern of anterior pituitary hormones is unique among the cytokines since it mimics almost completely the pattern of anterior pituitary response to stress (25) . The presence ofIL-2 receptors on the various cell types was considered to be the most likely explanation for the effects of IL-2 on the secretion of the various pituitary hormones (25) . From our experiments, it is apparent that in addition to the corticotrophs, other pituitary cell types, that remain to be characterized, express the IL-2R.
Five distinct transcripts, with lengths from 1.7 to 4.7 kb (41 ) or fourtranscripts (4.5, 3.5, 2.2, and 1.5 kb) (42) ofIL-2R mRNA, in which the longest transcript predominates, were detected in IL-2R-positive T cells when the same mouse IL-2R cDNAs as used in this study were employed. In human cells, two transcripts of 3.5 and 1.5 kb were detected with the hu IL-2R cDNA (43) . The different p55 IL-2R messages in the human are generated by the use of two principal transcription initiation sites, three different polyadenylation signals and alternative splicing of exon 4 (46, 49) . Some of these processes seem to occur in the mouse (41 ) . In our experiments, we detected only one (3.5 kb) or two (4.5 and 2.2 kb) transcripts in human and mouse pituitary cells, respectively. A predominant expression ofthe 3.5-kb transcript has been reported following interferon-gamma stimulation of monocytes (50) , suboptimal stimulation of normal T cells with PHA or PMA, or after the induction of IL-2R in the Jurkat T cell line by the tat gene of HTLV-II (49, 51') . Further studies will be required to determine the molecular mechanisms responsible for the mRNA FITC-conjugated monoclonal antibody was used diluted 1:100 (A) or 1:20 (B). Cells were stained after 24 h of stimulation with 10 nM PMA (A) or 10 nM CRH (B). Positive (arrows) and negative cells can be observed, including B, where a higher background is observed due to the higher antibody concentration. Fibroblasts present in the cultures were always negative. (C-F) Dual immunofluorescence staining was performed in cells cultured for 24 h at basal conditions. After fixing, cells were preabsorbed for I h with 10% normal goat serum and incubated overnight with a rabbit anti-ACTH (1:5,000) first antibody. After washing, a rhodamine-conjugated goat anti-rabbit IgG second antibody was added. Cells were washed and then treated with the same FITC-conjugated anti-rat IL-2 antibody as in A and B, diluted 1:50. Areas ofthe field were selected with positive cells (arrows) for the IL-2R (C and E) to facilitate the comparison with ACTH-positive cells (partial arrows, D and F). Comparing the same cells (Cwith D and E with F) colocalization of the ACTH-positive cells with positive IL-2R staining can be observed, but also other IL-2R-positive cells. species detected in the pituitary. This report is the first demonstration of IL-2R mRNA and membrane expression on pituitary cells and extends the previous description ofan a-chain of the IL-2R in these cells (27) . The pharmacological characterization of the pituitary IL-2R will be necessary to further understand its biological function. In particular, the possible expression of the p70 (,B) subunit of IL-2R and its interaction with the p55 chain, must be established.
In the AtT-20 cells, IL-2 mRNA was stimulated by CRH and PMA and in contrast to POMC gene expression, there were no detectable basal levels of IL-2 mRNA. In the adenoma cells, only the direct activation of protein kinase C with PMA produced levels ofboth IL-2 mRNA and IL-2 that were significantly different from basal. However, in two different adenoma cultures, CRH stimulation via the adenylate cyclase system also significantly increased the secretion of IL-2. It is known that the CRH response in Cushing's patients may reveal hyperresponsiveness, normal responsiveness, and even unresponsiveness (52). In the nine patients ofour study, the IL-2 production in response to CRH did not correlate with the POMC Interleukin-2 Pathway Expression in Anterior Pituitary Cells 1949 I expression in response to CRH. Further information on the signals and second messengers involved in pituitary IL-2 synthesis should provide an understanding ofwhether the particular IL-2 responses to CRH have any pathophysiological implications.
In conclusion, corticotrophic pituitary cells express both IL-2 and p55 IL-2R genes. IL-2 is secreted and its receptor is expressed in the membrane of these cells. In normal rat cell cultures, besides the corticotrophs, other pituitary cell types express the receptor. Our first demonstration of IL-2R expression in the membrane of pituitary cells not only provides evidence ofthe pituitary site ofaction of lymphocyte-produced or exogeneously administered IL-2, but also, in view of the IL-2 production by the tumor cells, of a possible paracrine or autocrine role of this lymphokine. It remains to be established whether the IL-2 production occurs in the normal pituitary or if it is intrinsic to the process of tumor development of these cells. Considering its growth factor properties, IL-2 could be involved in the control of pituitary cell proliferation.
